WTF: Treating neurodevelopmental diseases differently – why NTI164 offers new hope

What are ASD and Rett syndrome? How do they affect children and families? And what excites Professor Fahey most about NTI164’s future?

What are ASD and Rett syndrome? How do they affect children and families? Why is there a need for new treatment options in neurodevelopmental care? And what excites Professor Fahey most about NTI164’s future?

In this interview, Professor Michael Fahey, a leading Paediatric Neurologist and Clinical Geneticist at Monash Medical Centre, joins host Tylah Tully to answer all these questions and more, delving into his experience with Neurotech's (ASX:NTI) NTI164 drug in treating ASD and Rett syndrome.

As the first clinician to prescribe NTI164 during its clinical program, Professor Fahey shares powerful patient outcomes and his hope for a treatment that "enables people to be their best" without the side effects of conventional therapies.

He explains how NTI164 is showing early promise, with families reporting transformative changes.

"People were more alert, more able to participate... Families would tell us that they went out to dinner as a family for the first time," he said.

Professor Fahey believe the early clinical success really underscores the real-world impact of the drug could have, beyond clinical metrics.

Watch the video to learn more about the NTI164 drug candidate and Professor Fahey's key takeaways from the clinical program.

This video was developed in collaboration with Neurotech, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as WTF: Treating neurodevelopmental diseases differently – why NTI164 offers new hope